TRF ‐16 Inhibits Lung Cancer Progression by Hindering the N6 ‐Methyladenosine Modification of CPT1A mRNA
Journal of Cellular and Molecular Medicine · 2024-12 · 28 (24)
DOI: 10.1111/jcmm.70291 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 16.12.2024. Verfasst von Jiankui Ye und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, The Affiliated Lihuili Hospital of Ningbo University, Zhejiang, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Gene Expression Regulation, Neoplastic, Cell Proliferation, RNA, Messenger. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hubei Chen-Xiaoping Science Foundation, Natural Science Foundation of Ningbo Municipality, the Medical Health Science and Technology Project of Zhejiang Provincial Health Commission.
Abstract (Originalsprache)
Transfer RNA‐derived fragments (tRFs) are a new class of small non‐coding RNAs. Recent studies suggest that tRFs participate in some pathological processes. However, the biological activities and processes of tRFs in lung cancer cells remain mainly unclear. In the present investigation, we employed tRNA‐derived small RNA (tsRNA) sequencing to predict differentially expressed tsRNAs in lung cancer cells, and nine tsRNAs with significant expression alterations were validated using qPCR. Wound healing, colony formation, transwell invasion and CCK‐8 assays were performed to detect the effects of tRF‐16 on cell function. Western blotting evaluated the relationship between tRF‐16 and the IGF2BP1 axis. Our findings demonstrated that tRF‐16 expression was substantially downregulated in lung cancer cells. TRF‐16 could inhibit lung cancer cells' ability to increase, migrate, invade and obtain radiation resistance. Furthermore, tRF‐16 decreases the stability of CPT1A by impairing the binding of IGF2BP1 to CPT1A. As a result, the fatty acid metabolism in lung cancer cells was inhibited. Finally, tRF‐16 also inhibits lung cancer cell proliferation in vivo. This study shows that tRF‐16 plays a crucial regulatory role in the proliferation of lung cancer cells and may represent a novel avenue for their regulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, The Affiliated Lihuili Hospital of Ningbo University, Zhejiang, China.
- Health Science Center, Ningbo University, Zhejiang, China.
- Department of Thoracic Surgery, The Affiliated Hospital of Medical School of Ningbo University, Zhejiang, China.
ORCID-Profile: Zhuowei Shao, Shibo Wu
Förderung
- Hubei Chen-Xiaoping Science Foundation
- Natural Science Foundation of Ningbo Municipality
- the Medical Health Science and Technology Project of Zhejiang Provincial Health Commission
Zitieren
APA
Ye, J., Chen, Y., Shao, Z., Wu, Y., Li, Y., Fang, S., & Wu, S. (2024). TRF ‐16 Inhibits Lung Cancer Progression by Hindering the N6 ‐Methyladenosine Modification of CPT1A mRNA. Journal of Cellular and Molecular Medicine, 28(24). https://doi.org/10.1111/jcmm.70291
Vancouver
Ye J, Chen Y, Shao Z, Wu Y, Li Y, Fang S, et al. TRF ‐16 Inhibits Lung Cancer Progression by Hindering the N6 ‐Methyladenosine Modification of CPT1A mRNA. Journal of Cellular and Molecular Medicine. 2024;28(24). doi:10.1111/jcmm.70291
BibTeX
@article{Ye2024,
author = {Ye, Jiankui and Chen, Yu and Shao, Zhuowei and Wu, Yili and Li, You and Fang, Shuai and Wu, Shibo},
title = {TRF ‐16 Inhibits Lung Cancer Progression by Hindering the N6 ‐Methyladenosine Modification of CPT1A mRNA},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
volume = {28},
number = {24},
doi = {10.1111/jcmm.70291}
}
EUVIMED